Buchang Pharmaceutical: Yangzheng Heji obtains Malaysia drug registration certificate

Buzhang Pharmaceutical Announcement. Recently, the company’s wholly owned subsidiary, Yangling Buzhang Pharmaceutical Co., Ltd.,’s product Yangzheng Heji meets the registration standards for traditional Chinese medicine in Malaysia and has obtained the drug registration certificate approved and issued by the Malaysian Drug Control Authority. The sales performance of Yangzheng Heji for the most recent one-year period and latest interim period is as follows: In 2024, the sales revenue was 47.0947 million yuan, accounting for 0.43% of operating revenue; from January to September 2025, the sales revenue was 39.2656 million yuan, accounting for 0.46% of operating revenue. The registration certificate for Yangzheng Heji, approved and issued by the Malaysian Drug Control Authority, indicates that the company is qualified to sell this product in Malaysia as a traditional Chinese medicine, which will have a positive impact on the company’s expansion into overseas markets.